Short-term cellular effects induced by castration therapy in relation to clinical outcome in prostate cancer

British Journal of Cancer

Volumn 77, Issue 4, 1998, Pages 670-675

  Stattin, P ^a   Westin, P ^a   Damber, J E ^a   Bergh, A ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

Castration therapy; Cellular effects; Prostate neoplasms

Indexed keywords

KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN P53;

APOPTOSIS; ARTICLE; CASTRATION; CLINICAL ARTICLE; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; TUMOR BIOPSY;

EID: 0031965135     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.107     Document Type: Article

References (30)

1. Bladou F, Vessela RL, Buhler KR, Ellis WJ, True LD and Lange PH (1996) Cell proliferation and apoptosis during prostatic tumor xenograft involution and regrowth after castration. Int J Cancer 67: 785-790
2. Bostwick DG, Burke HB, Wheeler TM, Chung LW, Bookstein R, Pretlow TG, Nagle RB, Montironi R, Lieber MM, Veltri RW, Grizzle WE and Grignon DJ (1994) The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials. J Cell Biochem 19 (suppl): 283-289
3. Colombel M, Symmans F, Gil S, O'Toole KM, Chopin D, Benson M, Olsson CA, Korsmeyer S and Buttyan R (1993) Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 143: 390-400
4. Dhom G and Degro S (1982) Therapy of prostatic cancer and histopathologic follow-up. Prostate 3: 531-542
5. Fowler Jr JE, Pandey P, Seaver LE, Feliz TP and Braswell NT (1995) Prostate specific antigen regression and progression after androgen deprivation for localized and metastatic prostate cancer. J Urol 153: 1860-1865
6. Gleave ME, Hsich J-T, Wu H-C, von Eschenbach AC and Chung LWK (1992) Serum prostate specific antigen levels in mice hearing human prostate LNCaP tumours are determined by tumor volume and endocrine and growth factors. Cancer Res 52: 1598-1605
7. Greenblatt MS, Bennert WP, Hollstein M and Harris CC (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878
8. Kerr IE, Wyllie AH and Currie AR (1972) Apoptosis: a basic biological phenomenon with wide ranging implications in tissue kinelics. Br J Cancer 26: 239-257
9. Krajevvska M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, Song K, Kitada S and Reed JC (1996) Immunohistochemical analysis of bcl 2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 148: 1567-1576
10. Kyprianou N and Isaacs JT (1988) Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 122: 552-562
11. Kyprianou N, English HF and Isaacs JT (1990) Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res 50: 3748-3753
12. Landström M, Bergh A, Tomic R and Damber JE (1990) Estrogen treatment combined with castration inhibits tumor more effectively than castration alone in the Dunning R-3327 rat prostatic adenocarcinoma. Prostate 17: 57-68
13. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LWK, Hsieh JT, Tu SM and Campbell ML (1992) Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52: 6940-6944
14. Mostofi FK, Sesterhenn IA and Sobin LH (1980) International Histological Classification of Prostate Tumours. WHO: Geneva
15. Norusis MJ (1993) SPSS for Windows. SPSS: Chicago
16. Owen-Schaub LB, Radinsky R, Kruzel E, Berry K and Yonehara S (1994) Anti-Fas on nonhematopoetic tumors: levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness. Cancer Res 54: 1580-1586
17. Petros JA and Andriole GL (1993) Serum PSA after antiandrogen therapy. Urol Clin N Am 20: 749-756
18. Pietenpol JA, Papadopoulos N, Markowitz S, Wilson JKV, Kinzler KW and Vogelstein B (1994) Paradoxical inhibition of solid tumor cell growth by bcl-2. Cancer Res 54: 3714-3717
19. Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS and Buttyan R (1995) Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 55: 4438-4445
20. Resnick MI and Grayhack JT (1975) Treatment of stage IV carcinoma of the prostate. Urol Clin N Am 2: 141-161
21. Stattin P, Bergh A, Karlberg L, Nordgren H and Damber JE (1996a) p53 immunoreactivity as prognostic marker for cancer specific survival in prostate cancer. Eur Urol 30: 65-72
22. Stattin P, Damber JE, Karlberg L, Nordgren H and Bergh A (1996b) Bcl-2 immunoreactivity in prostate tumorigenesis in relation to prostatic intraepithelial neoplasia. Grade, hormonal status, metastatic growth and survival. Urol Res 24: 257-264
23. Suzuki A, Matsuzawa A and Iguchi T (1996) Down regulation of Bcl-2 is the first step on Fas-mediated apoptosis of male reproductive tract. Oncogene 13: 31-37
24. UICC (1992) TNM Classification of Malignant Tumours, 4th edn. Hermanek P and Sobin LH (eds). Springer: Berlin
25. Vairo G, Innes KM and Adams JM (1996) Bcl-2 has a cell cycle inhibitory function separable from its enhancement of cell survival. Oncogene 13: 1511-1519
26. van Werden WM, van Kreuningen A, Elissen NMJ, de Veermeji M, Jong FH, van Steenbrugge GJ and Schröder FH (1993) Castration-induced changes in morphology, androgen levels, and proliferative activity of human prostate cancer tissue grown in athymic mice. Prostate 23: 149-164
27. Vesalainen S, Lipponen P, Talja M and Syrjänen K (1994) Historical grade, Perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur J Cancer 30A: 1797-1803
28. Westin P, Stattin P, Damber JE and Bergh A (1995a) Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors. Am J Pathol 146: 1368-1375
29. Westin P, Brändström A, Damber JE and Bergh A (1995b) Castration plus oestrogen treatment induces but castration alone suppresses epithelial cell apoptosis in an androgen-sensitive prostatic adenocarcinoma. Br J Cancer 72: 140-145
30. Westin P, Lo P, Marin MC, Fernandes A, Sarkiss M and McDonnell TJ (1997) Bcl-2 expression confers androgen independence in an androgen sensitive prostatic carcinoma in vivo. Int J Oncol in press